Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol.
Por:
Bernal-Soriano MC, Parker LA, López-Garrigos M, Hernández-Aguado I, Caballero-Romeu JP, Gómez-Pérez L, Alfayate-Guerra R, Pastor-Valero M, García N and Lumbreras B
Publicada:
1 oct 2019
Resumen:
Prostate-specific antigen (PSA) is the main tool for early detection, risk stratification and monitoring of prostate cancer (PCa). However, there are controversies about the use of PSA as a population screening test because of the high potential for overdiagnosis and overtreatment associated. The net benefit of screening is unclear and according to the available recommendations, it should be offered to well-informed men with an adequate health status and a life-expectancy of at least 10 years or to men at elevated risk of having PCa. In addition, the factors that influence test results are unclear, as is impact of false positive or negative results on patient health.Our objective is to assess the clinical and analytical factors associated with the presence of false positive and false negative results and the diagnostic/therapeutic process followed by these patients.
Filiaciones:
Bernal-Soriano MC:
CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Department, Miguel Hernández University of Elche
Parker LA:
CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Department, Miguel Hernández University of Elche
López-Garrigos M:
Clinical Laboratory Department, University Hospital of San Juan de Alicante
Hernández-Aguado I:
CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Department, Miguel Hernández University of Elche
:
Urology Department, University Hospital of Vinalopó, Alicante, Spain and Alicante Institute for Health and Biomedical Research (ISABIAL)
Gómez-Pérez L:
Urology Department, University Hospital of San Juan de Alicante, Alicante, Spain and Pathology and Surgery Department, Miguel Hernández University of Elche
:
Clinical Laboratory Department
Pastor-Valero M:
CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Department, Miguel Hernández University of Elche
:
Urology Department, University General Hospital of Alicante, Alicante, Spain
Lumbreras B:
CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Department, Miguel Hernández University of Elche
Gold, Green Published
|